ClinTec International celebrates further global expansion and long service awards in clinical excellence
![](/46/pdcnewsitem/03/78/33/unnamed.png)
Company on track to deliver its 25% revenue growth target for this year.
ClinTec International celebrated its exceptional year of international growth with Glasgow’s Lord Provost, guests, Country Managers and Directors from over 40 countries, at the ClinTec International Global Conference held in Glasgow last week. Attended by ClinTec International staff and The Right Honourable Lord Provost of Glasgow, Sadie Docherty, the 4-day event celebrated Excellence in Clinical Research Long Service Awards.
ClinTec International is a success story for British business and has recently been recognised as the “UK’s Best Full Service Clinical Research Organisation” at the Healthcare & Pharmaceuticals Awards 2015, organised by Global Health & Pharma. This sits alongside the previously received Queens Award for Enterprise and the 2015 Business Woman of the Year at the Glasgow Business Awards. Commenting on ClinTec International’s growth, the Lord Provost said “ClinTec International has had an exceptional year of growth and they are a great asset to the UK business sector. These awards show the diversity and quality of the team, which has grown together to develop the global business ClinTec International is today.”
ClinTec International is dedicated to nurturing its employees giving them the opportunity to express their talents and capabilities. Building strong teams and promoting group work, along with open minded, individual thinking was always one of the priorities for ClinTec International. The company fosters an open communication culture at all levels without any discriminations, giving the opportunity for everyone to express their opinion.
Bobby Bal, Chief Business Officer said, “This has been an amazing year for us as ClinTec International has expanded its operations into over 50 countries. ClinTec International now has new entities in Japan, Canada, South Korea, New Zealand and Hong Kong. This success lies with our people and their amazing dedication. At ClinTec International we are committed to developing our employees and we are convinced that our employees are our greatest asset. ClinTec International employees work in several international project teams and contribute towards delivering excellence to our clients, who include 7 of the top 10 pharmaceutical and leading biotech companies.”
Founded in 1997 by the Entrepreneur Dr Rabinder Buttar, ClinTec International now operates in over 50 countries. This exceptional growth is continuing as the company is on track to deliver its 25% revenue growth target for this year.
Dr Rabinder Buttar said, “Our people are our greatest asset as we continue to deliver quality global clinical solutions in our fast, flexible and focused way. With our clients, we continue to align ourselves with their needs to deliver exceptional outcomes, which is due to the strength of our team as they innovate and build. Our Global Management Conference is a celebration of what we have achieved, our cultural values and a reminder of what has made us successful. Keeping this balanced view will continue to guide us as ClinTec International continues to deliver fantastic results and sustained organic growth.”
A key step in ClinTec International’s recent African expansion has been the opening of the new office in Johannesburg. This strategic development is allowing ClinTec International to offer enhanced personalised service delivery across Africa. Presentation of the Corporate Achievement Award, won by ClinTec International at the recent African Achievement Awards for its efforts in helping to develop business and achieve growth within Africa was performed at the ClinTec International Global Conference. Beltus Etchu, Chair of African Forum Scotland, said, “This is a most exciting and opportune time for dynamic companies to be active in the African continent. ClinTec International has demonstrated both the insight and foresight to prepare themselves to capture this window of opportunity. They have made marvellous strides in pursuing their ethical and totally professional approach to growing their clinical research business in South Africa, Malawi and now into Kenya. We look forward in the coming years, to assisting ClinTec International further grow into Central and Western Sub-Saharan Africa.’’
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance